Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ10091010-0,98
KB105110541,25
PKN57,0857,10,09
Msft-0,58
Nokia4,7294,734-0,63
IBM0,44
Mercedes-Benz Group AG60,4160,434,14
PFE-0,24
13.02.2025 9:50:00
Indexy online
AD Index online
select
AD Index online
 

  • 12.02.2025
Cytosorbents (NASDAQ Cons)
Závěr k 12.2.2025 Změna (%) Změna (USD) Objem obchodů (ks)
1,15 7,48 0,08 220 006
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 13.02.2025
Popis společnosti
Obecné informace
Název společnostiCytosorbents Corp
TickerCTSO
Kmenové akcie:Ordinary Shares
RICCTSO.O
ISIN-
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series B
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 07.03.2024 186
Akcie v oběhu k 02.12.2024 54 830 146
MěnaUSD
Kontaktní informace
Ulice305 COLLEGE ROAD EAST
MěstoPRINCETON
PSČ08540
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 733 298 885

Business Summary: CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Cytosorbents Corp revenues increased 5% to $29.1M. Net loss decreased 43% to $12.8M. Revenues reflect CytoSorb and other sales segment increase of 59% to $29.1M. Lower net loss reflects Research and development decrease of 52% to $5.6M (expense), Foreign Exchange Gain/Loss–Non-Business increase from $734K (expense) to $680K (income).
Odvětvová klasifikace
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSMedical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICS2007Electromedical Apparatus Mfg
NAICS2007Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Medical, Dental and Hospital Equipment and Supplies Wholesalers
SICSurgical And Medical Instruments
SICElectromedical Equipment
SICMedical And Hospital Equipment



  • Poslední aktualizace: 13.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Operating OfficerVincent Capponi66
Chief Executive Officer, DirectorPhillip Chan53
Chief Financial OfficerPeter Mariani6014.08.202414.08.2024
Chief Medical OfficerEfthymios Deliargyris5501.05.202001.05.2020